<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649788</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0540</org_study_id>
    <secondary_id>ANSM</secondary_id>
    <nct_id>NCT04649788</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Axillary Vein Access Versus Cephalic Venous Cutdown for Implantation of Cardiac Electronic Devices.</brief_title>
  <official_title>Prospective Randomized Comparison of Efficacy and Safety of Ultrasound-guided Axillary Vein Access Versus Cephalic Venous Cutdown for Implantation of Cardiac Electronic Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous access is a fundamental step in lead insertion for endovenous cardiac implantable&#xD;
      electronic devices (CIED). Cephalic vein cutdown is the most widely used technique in Europe.&#xD;
      Ultrasound-guided axillary vein access is a promising alternative but there is a lack of&#xD;
      clinical evidence supporting this technique.&#xD;
&#xD;
      The purpose of this study is to compare the efficacy and safety of ultrasound-guided axillary&#xD;
      vein access versus cephalic venous cutdown for implantation of endovenous CIED.&#xD;
&#xD;
      Half of patients is implanted using an ultrasound-guided axillary vein puncture. The other&#xD;
      half is implanted using a cephalic vein cutdown. After venous access is achieved,&#xD;
      implantation procedure is identical in the two arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of venous access</measure>
    <time_frame>Intervention time (day 0)</time_frame>
    <description>This outcome is measured by the operator during the intervention. It is the ability to successfully cannulate the vein and have all needed guidewire in the right atrium using the assigned venous access technique.&#xD;
The outcome is a binary value: success or failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to venous access</measure>
    <time_frame>Intervention time (day 0)</time_frame>
    <description>Time from cutaneous incision to reach the right atrium with all needed guidewire using the assigned venous access technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>Intervention time (day 0)</time_frame>
    <description>Time from cutaneous incision to skin suture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>Intervention time (day 0)</time_frame>
    <description>Duration of fluoroscopy use during intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>X-Ray exposure</measure>
    <time_frame>Intervention time (day 0)</time_frame>
    <description>X-ray exposure during intervention, measured in mGycm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication</measure>
    <time_frame>Intervention time (day 0)</time_frame>
    <description>All implant related complications including brachial plexus palsy, major pocket hematoma (hematoma requiring evacuation or transfusion or prolonged hospitalization), pneumothorax, hemothorax, pericardial effusion, lead dislodgement, device infection, venous thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac implantable electronic device (CIED) related infection</measure>
    <time_frame>Month 3</time_frame>
    <description>Local and systemic signs of CIED related infection will be monitored during follow-up. The definition and classification of CIED related infection are based on the current guideline and expert consensus statement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pacemaker</condition>
  <condition>Implantable Cardioverter-defibrillator</condition>
  <arm_group>
    <arm_group_label>Ultrasound-guided axillary vein access</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of patients will receive the cardiac implantable electronic device with ultrasound-guided axillary venous access.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cephalic vein access</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of patients will receive the cardiac implantable electronic device with cephalic venous access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound-guided axillary vein access</intervention_name>
    <description>Venous access is performed through ultrasound-guided axillary vein puncture and Seldinger technique. After venous access is obtained, a guide-wire is advanced through the access needle, and the tip of the guide-wire is positioned in the right cardiac atrium.</description>
    <arm_group_label>Ultrasound-guided axillary vein access</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cephalic vein access</intervention_name>
    <description>Venous access is performed through a cephalic vein cutdown approach. After venous access is obtained, a guide-wire is advanced and the tip of the guide-wire is positioned in the right cardiac atrium.</description>
    <arm_group_label>Cephalic vein access</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Indication for endovenous pacemaker or cardioverter-defibrillator (single or double&#xD;
             room)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previously implanted endocardial lead&#xD;
&#xD;
          -  Indication for cardiac resynchronization therapy&#xD;
&#xD;
          -  Impossibility of venous access&#xD;
&#xD;
          -  Unable/unwilling to provide informed consent&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Participating in another clinical study which can interfere with this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Charles</last_name>
    <phone>+33472071672</phone>
    <email>paul.charles@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathieu MONTOY</last_name>
    <phone>+33472072537</phone>
    <email>Mathieu.montoy@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul CHARLES</last_name>
      <phone>+33472071672</phone>
      <email>paul.charles@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathieu MONTOY</last_name>
      <phone>+33472072537</phone>
      <email>Mathieu.montoy@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Paul CHARLES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pacemaker</keyword>
  <keyword>implantable cardioverter-defibrillator</keyword>
  <keyword>axillary vein</keyword>
  <keyword>cephalic vein</keyword>
  <keyword>ultrasound</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

